featured
PEAK: A Randomized Phase 2 Study of mFOLFOX6 With Either Panitumumab or Bevacizumab as First-Line Treatment in Patients With Unresectable Wild-Type KRAS Metastatic Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: